Novel Inflammatory Biomarkers in Cardiovascular Therapeutics.
Inflammation has been established as an important determinant of cardiovascular disease progression. Currently, clinical examination, laboratory and imaging tests are invaluable for the diagnosis, prognosis and disease monitoring. Novel inflammatory biomarkers are also used to better restratify patients in risk groups but their potential to guide treatment decisions and management of patients has not been extensively evaluated. Therefore, in this review article we present the most recent data concerning the use of inflammatory biomarkers in cardiovascular therapeutics.
Vicky
V
Tsigkou
Gerasimos
G
Siasos
Evangelos
E
Oikonomou
Marina
M
Zaromitidou
George
G
Latsios
Manolis
M
Vavuranakis
Spyridon
S
Deftereos
Michael W
MW
Cleman
Eleni
E
Kokkou
Maria
M
Limberi
Stathis
S
Dimitropoulos
Thodoris
T
Zografos
Smaragdi
S
Marinaki
Christodoulos
C
Stefanadis
Dimitris
D
Tousoulis
D000818:Animals; D015415:Biomarkers / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000378:metabolism*; D006801:Humans; D006949:Hyperlipidemias / Q000378:metabolism*; D007249:Inflammation / Q000378:metabolism
D015415:Biomarkers